• long-acting reversible contraception
• long-acting progestogens
• sayana press

Pfizer would like to acknowledge the case study titled ‘Sayana Press and a case of likely lipoatrophy’1 published online in BMJ Sexual & Reproductive Health in June 2018.

Sayana Press (medroxyprogesterone acetate) is indicated for long-term female contraception and may be administered by a healthcare professional (HCP) or, when considered appropriate by the HCP, self-injected by the patient, with medical follow up as necessary in accordance with local clinical guidance. Each subcutaneous injection prevents ovulation and provides contraception for at least 13 weeks (+/– 1 week).2

The Sayana Press Summary of Product Characteristics states under ‘Section 4.8 Undesirable effects’ that injection-site reactions such as persistent injection-site atrophy/indentation/dimpling, injection-site nodule/lump and injection-site pain/tenderness are commonly reported (occurring in ≥ 1/100 to <1/10) and lipodystrophy …